Last reviewed · How we verify

Darolutamide (BAY 1841788) — Competitive Intelligence Brief

Darolutamide (BAY 1841788) (Darolutamide (BAY 1841788)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal androgen receptor antagonist. Area: Oncology.

phase 3 Non-steroidal androgen receptor antagonist Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Darolutamide (BAY 1841788) (Darolutamide (BAY 1841788)) — Canadian Cancer Trials Group. Darolutamide is a non-steroidal androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Darolutamide (BAY 1841788) TARGET Darolutamide (BAY 1841788) Canadian Cancer Trials Group phase 3 Non-steroidal androgen receptor antagonist Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal androgen receptor antagonist class)

  1. Canadian Cancer Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Darolutamide (BAY 1841788) — Competitive Intelligence Brief. https://druglandscape.com/ci/darolutamide-bay-1841788. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: